180. Evaluation of the Cost-effectiveness of Ofatumumab for Relapsing Multiple Sclerosis in the United Arab Emirates
Jihad Inshasi,Yomna Nowier,Evelina A. Zimovetz,Ahmed Moussa,Ahmed Shatila,Ali Hassan,Mohamed Farghaly,Mona Thakre,Mustafa Shakra,Sara Al Dallal,Suzan I.A. Noori,Tayseer Zain Alabdin,Sherouq Khattab,Dayane Daou,Bassem Yamout
DOI: https://doi.org/10.1016/j.msard.2024.106141
IF: 4.808
2024-12-15
Multiple Sclerosis and Related Disorders
Abstract:Background/Objective(s) Multiple sclerosis (MS) is a chronic autoimmune disease that causes inflammation and destruction of myelin sheaths in the central nervous system. It profoundly affects the quality of life for individuals with the disease and their families. Relapsing MS (RMS) includes relapses and encompasses clinically isolated syndrome, relapsing-remitting MS, and relapsing secondary progressive MS (SPMS), while progressive forms consist of non-relapsing SPMS and primary progressive MS (PPMS). Ofatumumab is a highly effective disease modifying treatment (DMT) for treating RMS in the United Arab Emirates (UAE). An economic evaluation is crucial for healthcare decision-makers considering the costs and chronic nature of MS.This study aims to assess the cost-effectiveness of ofatumumab from the UAE payer perspective in comparison to other available DMTs. Material(s) and Method(s) A discrete time Markov model, built in Microsoft Excel, was employed to simulate expanded disability status scale (EDSS) health states, which included EDSS 0 (normal neurological function) to EDSS 10 (indicating death). The model structure was adapted from a pre-existing ofatumumab model designed for country-specific adaptations. Model used an annual cycle length and a 65-year time horizon. Patients with RMS distributed between different EDSS health states, as observed in ASCLEPIOS I & II trials, entered the model. Patients could transition between EDSS states, discontinue treatment, experience relapses or die. Treatment effects were incorporated by differentiating in 6-months confirmed disability progression, annualized relapse rate risk, and treatment discontinuation rates. Costs and utilities were assigned to each EDSS state and treatment-related adverse events. The model was developed from the UAE payer's perspective and included only direct medical costs. As there was no country-specific value available, a willingness-to-pay threshold of AED 369,854/quality adjusted life years (QALY) was assumed, corresponding to twice the per capita gross domestic product. Costs and outcomes were discounted at 3.5%. The model calculated outcomes such as total costs, QALYs, incremental costs, incremental QALYs, and incremental cost-effectiveness ratio (ICER) based on the base-case input values. Sensitivity analyses, including scenario analyses, one-way sensitivity analysis, and probabilistic sensitivity analyses (PSA), were performed. The model structure and input parameters underwent expert reviews by clinical and health economics experts in the UAE for face validity. Result(s) In base case analysis, ofatumumab was dominant (less costly and more effective) over ocrelizumab, dimethyl fumerate, fingolimod, and IV natalizumab. Additionally, ofatumumab was cost-effective compared with teriflunomide, fingolimod (generic), glatiramer acetate, interferons, and best supportive care. Ofatumumab resulted in an ICER of AED 713,068 per QALY when compared with cladribine. However, ofatumumab was dominant over cladribine in a scenario where retreatment rate was increased to 36.6% from year 5 onwards. The key determinants of net monetary benefit were progression efficacies and treatment discontinuation rates. The results of PSA were consistent with base case analysis. Conclusion(s) The cost-effectiveness, favorable safety profile, and convenient administration of ofatumumab make it a valuable treatment option for patients with relapsing multiple sclerosis (RMS). Future economic evaluations should consider the switching patterns among different DMTs.
clinical neurology